Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Simon Chowdhury

Showing results (91-100 of 151) with videos related to

Pageof 16
Sort By:
European Journal of Cancer (Oxford, England : 1990)|September 14, 2023
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN studyAxel S Merseburger, Neeraj Agarwal, Amitabha Bhaumik, et al.
The Journal of Urology|July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN TrialSoumyajit Roy, Yilun Sun, Kim N Chi, et al.
European Urology|October 15, 2022
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with RucaparibAndrea Loehr, Arif Hussain, Akash Patnaik, et al.
European Urology|September 10, 2020
Apalutamide and Overall Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
Acta Oncologica (Stockholm, Sweden)|August 31, 2017
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) InvestigatorsJihane Boustani, Aurélie Bertaut, Matthew D Galsky, et al.
European Urology Focus|February 11, 2019
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted TherapyPeter E Hall, Scott T C Shepherd, Janet Brown, et al.
Asian Journal of Andrology|June 16, 2023
Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trialByung Ha Chung, Jian Huang, Hiroji Uemura, et al.
The New England Journal of Medicine|February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
JAMA Oncology|June 3, 2016
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal CancerThomas Powles, Naveed Sarwar, Andrew Stockdale, et al.
The Lancet. Oncology|October 4, 2019
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 studyNeeraj Agarwal, Kelly McQuarrie, Anders Bjartell, et al.
Pageof 16

Showing results (91-100 of 151) with videos related to

Sort By:
Pageof 16
European Journal of Cancer (Oxford, England : 1990)|September 14, 2023
Apalutamide plus androgen deprivation therapy in clinical subgroups of patients with metastatic castration-sensitive prostate cancer: A subgroup analysis of the randomised clinical TITAN studyAxel S Merseburger, Neeraj Agarwal, Amitabha Bhaumik, et al.
The Journal of Urology|July 26, 2024
Early Prostate-Specific Antigen Response by 6 Months Is Predictive of Treatment Effect in Metastatic Hormone Sensitive Prostate Cancer: An Exploratory Analysis of the TITAN TrialSoumyajit Roy, Yilun Sun, Kim N Chi, et al.
European Urology|October 15, 2022
Emergence of BRCA Reversion Mutations in Patients with Metastatic Castration-resistant Prostate Cancer After Treatment with RucaparibAndrea Loehr, Arif Hussain, Akash Patnaik, et al.
European Urology|September 10, 2020
Apalutamide and Overall Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
Acta Oncologica (Stockholm, Sweden)|August 31, 2017
Radical cystectomy or bladder preservation with radiochemotherapy in elderly patients with muscle-invasive bladder cancer: Retrospective International Study of Cancers of the Urothelial Tract (RISC) InvestigatorsJihane Boustani, Aurélie Bertaut, Matthew D Galsky, et al.
European Urology Focus|February 11, 2019
Radiological Response Heterogeneity Is of Prognostic Significance in Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor-targeted TherapyPeter E Hall, Scott T C Shepherd, Janet Brown, et al.
Asian Journal of Andrology|June 16, 2023
Apalutamide for metastatic castration-sensitive prostate cancer: final analysis of the Asian subpopulation in the TITAN trialByung Ha Chung, Jian Huang, Hiroji Uemura, et al.
The New England Journal of Medicine|February 9, 2018
Apalutamide Treatment and Metastasis-free Survival in Prostate CancerMatthew R Smith, Fred Saad, Simon Chowdhury, et al.
JAMA Oncology|June 3, 2016
Safety and Efficacy of Pazopanib Therapy Prior to Planned Nephrectomy in Metastatic Clear Cell Renal CancerThomas Powles, Naveed Sarwar, Andrew Stockdale, et al.
The Lancet. Oncology|October 4, 2019
Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 studyNeeraj Agarwal, Kelly McQuarrie, Anders Bjartell, et al.
Pageof 16